Print 11 December 2014
SANTA CLARA, Calif., Dec. 11, 2014 /PRNewswire/ — Miramar Labs®, Inc., a leading medical device manufacturer and maker of the miraDry® System, today announced the results of recently published 2-year data showing that miraDry efficacy observed at 30 days remains stable through 2 years.
The miraDry System delivers energy non-invasively to the area under the arm where sweat glands reside, creating localized heat to destroy and eliminate those glands. Since sweat glands do not regenerate, these results are expected to be permanent.
The study published in the journal Dermatologic Surgery reported1:
Since its launch, the miraDry system has been used in over 30,000 treatments worldwide and currently boasts a 90% patient satisfaction rating in commercial use, among the highest of all aesthetic procedures.
“Since sweat and odor glands do not regenerate, these results are expected to be permanent,” commented Michael Kleine, Miramar Labs President and CEO. “This is a tremendous breakthrough, not only for excessive sweaters, but for anyone who manages nuisance sweat and odor. Everyone sweats, but now, with miraDry, patients can choose not to.”
1. Lupin M. et. al. Dermatol Surg 2014; 40: 805-807
For more information, visit the miraDry website at www.miraDry.com, or follow miraDry on Facebook/miraDry and Twitter @miraDry.
About Miramar Labs:
Founded in 2006, Miramar Labs is a privately owned medical device company dedicated to bringing the next generation energy modality to the field of dermatology. Miramar Labs is the tenth company created by The Foundry, a leading medical device incubator based in Menlo Park, California. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company’s first priority is the treatment of excessive underarm sweat, a medical condition that significantly affects the quality of life of millions of people. Physicians and patients are encouraged to visit www.miradry.com for additional information about Miramar Labs.
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.
20 September 2017
19 September 2017